Biochemical response to bisphosphonate therapy in pagetic patients with skull involvement

Calcified Tissue International

Volumn 79, Issue 1, 2006, Pages 22-26

  Peris, P ^a   Alvarez, L ^a   Vidal, S ^a   Kasper, D ^b   Leeming, D J ^b   Monegal, A ^a   Martínez, M Angeles ^a   Pons, F ^a   Guanabens N ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

CTX; Bone marker; Tiludronate

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; PROCOLLAGEN; PROCOLLAGEN TYPE I AMINO TERMINAL PROPEPTIDE; TILUDRONIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BONE RADIOGRAPHY; BONE SCINTISCANNING; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; OPEN STUDY; OSSIFICATION; OSTEOLYSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; SKULL DISEASE; SPECTROPHOTOMETRY; STATISTICAL ANALYSIS; TREATMENT RESPONSE; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; CASE-CONTROL STUDIES; COLLAGEN TYPE I; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OSTEITIS DEFORMANS; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; PROSPECTIVE STUDIES; RADIONUCLIDE IMAGING; SKULL; TECHNETIUM; TIME FACTORS; TREATMENT OUTCOME;

EID: 33746934212     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-005-0247-9     Document Type: Article

References (25)

1. Selby PL, Davie MWJ, Ralston SH, Stone MD (2002) Guidelines on the management of Paget's disease of bone. Bone 31:10-19
2. Siris E, Roodman G (2003) Paget's disease of bone. In: Favus MJ (ed) Primer on the Metabolic Bone Disease and Disorders of Mineral Metabolism, 5th ed. American Society for Bone and Mineral Research, Washington DC, pp 495-506
3. Alvarez L, Peris P, Guañabens N, Vidal S, Quintó L, Monegal A, Pons F, Ballesta AM, Muñoz-Gómez J (2004) Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment. Rheumatology 43:869-874
4. Papapoulos SE, Frolich M (1996) Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption. J Clin Endocrinol Metab 81:3993-3997
5. Patel S, Stone MD, Coupland C, Hosking DJ (1993) Determinants of remission of Paget's disease of bone. J Bone Miner Res 8:1467-1473
6. Khan SA, Mc Closkey EV, Nakatsuka K, Orgee J, Coombes GM, Kanis JA (1996) Duration of response with oral clodronate in Paget's disease of bone. Bone 18:185-190
7. Meunier PJ, Salson C, Mathieu L, Chapuy MC, Delmas P, Alexandre C, Charhon S (1987) Skeletal distribution and biochemical parameters of Paget's disease. Clin Orthop Relat Res 217:37-44
8. Harnick HIJ, Bijvoet OLM, Vellenga CJLR, Blanksma HJ, Frijlink WB (1986) Relation between signs and symptoms in Paget's disease of bone. QJM 58:133-151
9. Alvarez L, Peris P, Pons F, Guañabens N, Herranz R, Monegal A, Bedini JL, Deulofeu R, Martínez de Osaba MJ, Muñoz-Gómez J, Ballesta AM (1997) Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity. Arthritis Rheum 40:461-468
10. Smith SE, Murphey MD, Motamedi K, Mulligan ME, Resnik CS, Gannon FH (2002) Radiologic spectrum of Paget disease of bone and its complications with pathologic correlation. Radiographics 22:1191-1216
11. Alvarez L, Guañabens N, Peris P, Vidal S, Ros I, Monegal A, Bedini JL, Deulofeu R, Pons F, Muñoz-Gómez J, Ballesta AM (2001) Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease. Bone 29:447-452
12. Alexandersen P, Peris P, Guañabens N, Byrjalsen I, Alvarez L, Solberg H, Cloos PAC (2005) Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone. J Bone Miner Res 20:588-595
13. Coutris G, Cayla J, Rondier J, Talbot JN, Bonvarlet JP, Milhaud G (1975) Analyse des perturbations des voies principales du metabolism calcique dans la maladie de Paget: effets de l'administration de calcitonine. Rev Rhum Mal Osteoartic 42:759-767
14. Allen MR, Hock JM, Burr DB (2004) Periosteum: biology, regulation, and response to osteoporosis therapies. Bone 35:1003-1012
15. Solchaga LA, Cassieda P, Caplan AI (1998) Different response to osteo-inductive agents in bone marrow- and periosteum-derived cell preparations. Acta Orthop Scand 69:426-432
16. Everts V, Korper W, Jansen C, Steinfort J, Lammerse I, Heera S, Docherty AJ, Beertsen W (1999) Functional heterogeneity of osteoclasts: matrix metalloproteinases participate in osteoclastic resorption of calvarial bone but not in resorption of long bone. FASEB J 13:1219-1230
17. Alvarez L, Ricos C, Peris P, Guañabens N, Monegal A, Pons F, Ballesta AM (2000) Components of biological variation of biochemical markers of bone turnover in Paget's bone disease. Bone 26:571-576
18. Fledelius C, Johnsen AH, Cloos PAC, Bonde M, Qvist P (1997) Characterisation of urinary degradation products derived from type I collagen. J Biol Chem 272:9755-9763
19. Cloos PAC, Fledelius C (2000) Collagen fragments in urine derived from bone resorption are highly racemized and isomerized. A biological clock of protein ageing with clinical potential. Biochem J 345:473-480
20. Garnero P, Fledelius C, Gineyts E, Serre CM, Vignot E, Delmas PD (1997) Decreased beta-isomerization of the C-terminal telopeptide of type I collagen alpha 1 chain in Paget's disease of bone. J Bone Miner Res 12:1407-1415
21. Garnero P, Gineyts E, Schaffer AV, Seamen J, Delmas PD (1998) Measurement of urinary excretion of nonisomerized and b-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Arthritis Rheum 41:354-360
22. Langton AL, Ralston SH (2004) Management of Paget's disease of bone. Rheumatology 43:955-959
23. Guañabens N, Alvarez L, Cerdá D, Vidal S, Monegal A, Peris P, Ros I, Ballesta A, Pons F (2003) Similar effects of tiludronate and risedronate on Paget's disease activity assessed by bone markers. J Bone Miner Res 18(suppl 2):S388-S389
24. Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D (2005) Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 353:898-908
25. Donáth J, Krasznai M, Fornet B, Gergely PJr, Poór G (2004) Effect of bisphosphonates treatment in patients with Paget's disease of the skull. Rheumatology 43:89-94